AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03569449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-based visits
Description: Family partners will be restricted to working at the primary care clinic - communication will be restricted to telephone, text, and clinic visits
Study NCT03569449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard pediatric surveillance
Description: Monitoring is determined by standard pediatric practice. Behavioral screening is usually done annually.
Study NCT03569449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured, schedule-based visits
Description: Family Partners will utilize a predetermined schedule of contacts with families
Study NCT03569449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced pediatric surveillance
Description: In Massachusetts, behavioral screening is mandated at every pediatric visit, which for children in the target population (ages 3-12 years) is annually. With enhanced monitoring, Family Partners will screen children using validated instruments quarterly and communicate results to the child's care team
Study NCT03569449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology enhanced care coordination
Description: Behavioral: technology enhanced care coordination FPs will also have access to Act.MD, a cloud-based care coordination and communication tool that offers the potential to improve communication with families, schools, and the primary care site through administration of online questions, videoconferencing, and common portals that can be used by parents and multiple providers (e.g., FP, pediatrician, teacher).
Study NCT03569449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: :Individually-tailored visits
Description: Family Partners will be able to meet with families on an as-needed basis, with no predetermined schedule of contacts
Study NCT04342416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visiospatial Interference
Description: Behavioral: Brief cognitive intervention. A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) with instructions to engage in the task self-guided in the subsequent weeks.
Study NCT00696098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium butyrate
Description: 1 enema (60 ml) once daily containing 100mM
Study NCT03569449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-based visits and community visits
Description: In clinic-based visits the Family Partner is restricted to working at the primary care clinic and communication is restricted to telephone, text, and clinic visits. However in conditions with clinic based and community visits, the Family Partners will be available to meet families in their home and community (as well as the clinic), and accompany families to community-based meetings at school or childcare.
Study NCT03025477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CC0 - Carboplatin (IV) - Paclitaxel (IV)
Description: (6 cycles)
Study NCT03025477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC0 - Cisplatin (IP) - Epirubicin (IV)
Description: (6 cycles)
Study NCT03025477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CC>0 - Carboplatin (IV)- Paclitaxel (IV)
Description: * carboplatin (IV) - paclitaxel (IV) (3 cycles)~* Interval surgery~* Carboplatin (IV) - paclitaxel (IV) (3 cycles)
Study NCT03025477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)
Description: * Cisplatin (IV) - Epirubicin (IV) (3 cycles)~* Interval surgery :~  * if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles)~ * if CC>0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)
Study NCT01525862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon sinus dilation
Study NCT03047811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCR - T cell therapy
Description: Low dose group: 1 x 10 \^8 /kg T cell total reinfusion. High dose groups: 10 x 10 \^ 8 / kgT cell total reinfusion.
Study NCT04015570 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Volume Plasma Exchange
Description: PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity
Study NCT04015570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment (Albumin+High caloric diet)
Study NCT04015570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment (Albumin+High caloric diet)
Study NCT03419312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proclaim™ Elite 5: Burst - Washout - Sham
Description: All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106.
Study NCT03419312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proclaim™ Elite 5: Sham - Washout - Burst
Description: All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106.
Study NCT03353038 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D printed pillbox
Description: The research team interviewed the participant about their habits, routines, preferences, medications, and skills and abilities. Based on the interview, the research team designed and printed a customized 3D printed pillbox.
Study NCT02805465 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT Device and Bi-ventricular pacing
Description: Bi-ventricular pacing by a CRT device
Study NCT02805465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT Device and Bi-ventricular pacing
Description: Bi-ventricular pacing by a CRT device
Study NCT02805465 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT Device and His-bundle Pacing
Description: His-bundle pacing by a CRT device through the pacing lead at His-bundle region
Study NCT02805465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT Device and His-bundle Pacing
Description: His-bundle pacing by a CRT device through the pacing lead at His-bundle region
Study NCT00931125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab and vitrectomy
Description: ranibizumab 10mg/ml intravitreal injection, 0,05 ml
Study NCT00931125 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: vitrectomy without preoperative ranibizumab
Description: sham intravitreal injection before vitrectomy surgery
Study NCT02584062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no-touch fluid-air exchange
Study NCT00696098 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: 1 enema (60 ml) once daily containing 0.9%NaCl
Study NCT01181141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b (edoxaban)
Study NCT01181141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin sodium 20mg
Study NCT02582931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-guided SBRT
Study NCT02582931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 Questionnaire
Description: 30 questions with 28 questions having answers that range from 1 (not at all) to 4 (very much) and the other 2 questions have answers that range from 1 (very poor) to 7 (excellent)
Study NCT02582931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-OV28 Questionnaire
Description: 28 questions having answers that range from 1 (not at all) to 4 (very much)
Study NCT04368000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent prone positioning instructions
Description: Participants will be given instructions to lie in the prone position for a duration of 1-2 hours, every 4 hours while awake.
Study NCT04368000 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care positioning with no instructions
Description: Participants will not be given instructions to lie in the prone position for any duration.
Study NCT01909219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium picosulphate/magnesium Citrate
Description: Comparison of two different dosing regimens of sodium picosulphate/magnesium citrate
Study NCT04321278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + azithromycin
Description: Intervention Group: Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] + azithromycin \[500mg 1x/day\]) for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
Study NCT02584062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vitrectomy metrectomy and internal membrane peeling and gas tamponed
Study NCT00000407 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vocational counseling intervention
Study NCT00000407 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reading materials for control participants
Study NCT00000407 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: No education or behavioral intervention
Study NCT02789358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cryotherapy dosage
Description: Cryotherapy dosage: 180 seconds applications until block of the pulmonary vein plus 1 bonus freezing of 180 seconds
Study NCT02789358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental cryotherapy dosage
Description: cryotherapy dosage: applications time to block of the vein plus 60 seconds long until block of the vein plus 1 bonus freezing of 120 seconds
Study NCT02789358 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arctic Front Advance ST Cryoenergy Balloon Catheter
Description: Electrical isolation of pulmonary veins with Arctic Front Advance cryoballoon
Study NCT04321278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Active Control Group: Hydroxychloroquine. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
Study NCT02288039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Identity goal-based Intervention
Description: Phase 1: collaborative group discussion in order to establish what group members want to achieve by the end of their 8-week pulmonary rehabilitation programme. Phase 2: further collaborative group discussion with the emphasis on evaluating, monitoring, and providing feedback on goal attainment. Phase 3: focus group interviews with an emphasis on reviewing the goal setting process that patients have engaged with.
Study NCT02789358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Front Advance ST Cryoenergy Balloon Catheter
Description: Electrical isolation of pulmonary veins with Arctic Front Advance cryoballoon
Study NCT02789358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine triphosphate
Description: 12 mg of adenosine triphosphate are administrated intravenously to test dormant conduction in pulmonary veins apparently disconnected
Study NCT04358289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Participatory action research group in commune health center and community
Description: * Establish a participatory action research group~* Engagement with the group through participatory action research involving problem identification, planning change strategies, implementing strategies, and evaluation
Study NCT04358289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Antimicrobial stewardship program in hospitals
Description: The intervention activities in hospitals will include: training a health-worker in each of the participating hospitals to act as a facilitator or activator; forming an antibiotic stewardship group; meeting regularly and following an action-research cycle that includes problem identification, planning change strategies, implementing strategies, and evaluating strategies
Study NCT02789358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate
Description: 12 mg of adenosine triphosphate are administrated intravenously to test dormant conduction in pulmonary veins apparently disconnected
Study NCT02789358 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nECG platform Nuubo®
Description: 30 days electrocardiographic monitoring system to detect atrial fibrillation episodes after ablation
Study NCT02789358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nECG platform Nuubo®
Description: 30 days electrocardiographic monitoring system to detect atrial fibrillation episodes after ablation
Study NCT01498692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROMUS Element Coronary Stent System
Description: PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating)
Study NCT02658552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse
Description: Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
Study NCT01947283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DECIDE-PA
Description: The DECIDE-PA intervention teaches patients strategies for asking questions and communicating more effectively with their behavioral health care provider in order to improve shared decision making.
Study NCT01947283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DECIDE-PC
Description: The DECIDE-PC intervention trains providers in patient-centered communication techniques and encourages providers to be receptive to patients who take a more active role during the clinical encounter in order to improve shared decision making.
Study NCT05664503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions STOMA-M
Description: The training, which includes information on stoma care, maintenance of daily life activities, and complication management, was given to the patients in the experimental group via the STOMA-M.
Study NCT04507048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active educational intervention
Description: an active educational intervention will be provided in the experimental arm, consisting in the administration of a booklet (passive intervention) + an oral standardized explanation of the booklet given by a trained dermatologist for each center.
Study NCT04507048 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive educational intervention
Description: Administration of a booklet containing the explanation of 2 clinical rules for early detection of atypical melanocytic lesions: the ABCDE and the ugly duckling rules.
Study NCT03571750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Stronger Allies
Description: BSA was developed to model the educational and behavioral techniques commonly employed in the treatment of individuals with mood psychopathology. The psychoeducation portion uses Cognitive Behavioral Therapy principles to correct problematic ideas and behaviors related to PB/TB. More specifically, the program was designed to correct myths regarding PB/TB. The program emphasizes the idea that social interaction is a critical need, just like other basic needs such as the need for food and water. Participants are taught that negative beliefs about being isolated and being a burden are usually inaccurate. Following this, behavioral activation techniques are introduced as a way to decrease isolation and feelings of burdensomeness.
Study NCT03571750 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education Training
Description: In the HET condition, participants will spend approximately the same amount of time with a program that will present information regarding the importance and benefits of a maintaining a healthy lifestyle and then will provide guidelines to achieve a healthy lifestyle. HET is shown to engage participants with beneficial information while being inert with respect to the risk mechanisms of interest (i.e., PB/TB). The program covers a number of health related topics including: diet, alcohol use, water consumption, exercise, and sleep. The program reviews with the Participants how to monitor their own daily health habits, which will be reinforced by the Smartphone application.
Study NCT03962894 — intervention group
Intervention type: DRUG
Intervention: Prednisolone
Description: During a sequenced rollout protocol change for several EMS agencies, those agencies will adopt protocol change to administer prednisolone to children with asthma attacks in the prehospital environment prior to ED arrival.
Study NCT01642901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 5 mg zoledronic acid infused intravenously over two hours (2.5mg per hour), given only once, within 21 days of acute traumatic spinal cord injury.
Study NCT01642901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline 0.9%
Description: Infusion of equivalent volume of 0.9% normal saline to that of the reconstituted zoledronic acid, given only once over two hours, occurring within 21 days of acute traumatic spinal cord injury
Study NCT00510445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat Sodium (GRN163L)
Description: The starting dose of GRN163L for this study will be 3.2 mg/kg. Subsequent dose levels will be 4.8, 6, 7.5, 9, 11, and 13.5 mg/kg. The maximum dose to be administered will not exceed 13.5 mg/kg.~Paclitaxel and carboplatin will be administered on Day 2 of each 21-day cycle.
Study NCT02653443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets.
Description: Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
Study NCT01445561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (100,00 IU/m(2) SQ)
Description: 100,000 International Units/m2 SQ daily for 5 days
Study NCT00867568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: Three patients will be enrolled to receive single agent TPI 287 IV administered on Days 1, 8 and 15 of the first and second 28-day cycle. The starting dose of 90 mg/m2 (Dose Level 1) is 75% of the established adult MTD for this schedule in adults, which is 125 mg/m2. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.
Study NCT01007773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex
Description: Once this patient is deemed stable on the propofol infusion, the patient will be started on a dexmedetomidine infusion at 0.4 mcg/kg/hr. The dexmedetomidine infusion will be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -1 (maximum rate of 1.5 mcg/kg/hr). In the meantime, once sustained ICP control has been achieved, the initial sedative agent (usually propofol) will be weaned. Dexmedetomidine will be infused for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued. When the patient is ready to come off sedation, the dexmedetomidine will be weaned by 50% every hour over a 4-hour period to off.
Study NCT01007773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be initiated at 25 mcg/kg/min and titrated to achieve an ICP \< 20 mm Hg (up to a maximum of 75 mcg/kg/min). Propofol will be continued for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued.
Study NCT01007773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl will be initiated and titrated to achieve adequate pain control.
Study NCT01007773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be titrated to an ICP \< 20 mm Hg until achievement of sustained ICP control.
Study NCT04319432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice rest
Description: The first days will take place in hospitalization to assess patient complience to voice rest. Patients will be instructed to continue voice rest at home up to 7 days accourding to group allocation in the study. The confirmation of voice rest will relay on patient report (telephonic approval), after the voice rest period will end.
Study NCT02829931 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Stereotactic Irradiation
Description: Hypofractionated Stereotactic Irradiation (HFSRT) prior to nivolumab.